News
Honors | Wanbangde Pharmaceutical Group Named Again Among Zhejiang Province's Top 500 High-Tech Enterprises for Innovation Capability!
Date:
02 Dec,2023
Commissioned by the Zhejiang Provincial High-Tech Enterprise Association, the Zhejiang Provincial Institute of Science and Technology Information organized and conducted an evaluation of innovation capabilities among high-tech enterprises. Through a comprehensive comparison of multiple indicators, the institute identified the Top 500 Zhejiang High-Tech Enterprises in terms of innovation capability for 2023. Following 2022, Wanbangde Pharmaceutical Group Co., Ltd. has once again been proudly listed—and this year, its ranking climbed a remarkable 34 places from last year!
Honour
Top 500 High-Tech Enterprises in Zhejiang Province for Innovation Capability
Key Metrics of the 2022 Top 500 Companies
● Achieved operating revenue of 2,286.23 billion yuan, accounting for 34.2% of the total high-tech enterprises.
● Achieved tax and profit contributions of 484.76 billion yuan, accounting for 58.5% of the total high-tech enterprises.
● R&D expenditures totaled 162.44 billion yuan, accounting for 40.4% of the total investment by high-tech enterprises.
Overall Characteristics of the Top 500 Companies
The advantages in scale, technology, and economic efficiency have become even more pronounced: Operating scale continues to expand, with the top 500 companies achieving a new milestone in revenue—totaling 2,286.23 billion yuan in 2022, representing a robust 25.6% increase. Meanwhile, their technological edge keeps strengthening, boasting 157,239 valid patents at the end of the period, up 26.0%. Additionally, their economic benefits have grown significantly, delivering total profits and taxes of 484.76 billion yuan—a rise of 14.3%.
This inclusion on the list is both a strong recognition of Wanbangde Pharmaceutical Group's technological innovation capabilities and a significant boost to the company's competitiveness and brand influence.
As a company recognized on the list, Wanbangde Pharmaceutical Group regards innovation as the driving force behind its development. We prioritize R&D investment and the commercialization of technological breakthroughs, fostering robust core intellectual property rights and continuously enhancing our competitive edge through scientific and technological innovation. Looking ahead, the company will persistently unleash the innovative vitality of a high-tech enterprise, maintaining strong growth momentum while relentlessly pushing boundaries and forging new paths. Our ultimate goal is to become a key player in advancing scientific and technological innovation across the province, providing solid support for the region’s high-quality economic development!
Related Recommendations